Related references
Note: Only part of the references are listed.Long-term follow-up of mTOR inhibition for Erdheim-Chester disease
Francesco Pegoraro et al.
BLOOD (2020)
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
Gaurav Goyal et al.
BLOOD (2020)
Management and treatment options when facing malignant ureteral obstruction
Christian Tabib et al.
INTERNATIONAL JOURNAL OF UROLOGY (2020)
Erdheim-Chester disease: a rapidly evolving disease model
Francesco Pegoraro et al.
LEUKEMIA (2020)
Central nervous system involvement in Erdheim-Chester disease An observational cohort study
Fleur Cohen Aubart et al.
NEUROLOGY (2020)
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Eli L. Diamond et al.
NATURE (2019)
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients
Federica Maritati et al.
FRONTIERS IN IMMUNOLOGY (2019)
Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort
Fleur Cohen-Aubart et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF V600E mutation
Moozhan Nikpanah et al.
EUROPEAN RADIOLOGY (2018)
Arterial involvement in Erdheim-Chester disease A retrospective cohort study
Michel Villatoro-Villar et al.
MEDICINE (2018)
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
Fleur Cohen Aubart et al.
BLOOD (2017)
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults
Paul Milne et al.
BLOOD (2017)
The clinical spectrum of Erdheim-Chester disease: an observational cohort study
Juvianee I. Estrada-Veras et al.
BLOOD ADVANCES (2017)
Cardiac involvement in Erdheim-Chester disease: an MRI study
Davide Gianfreda et al.
BLOOD (2016)
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
J.-F. Emile et al.
BLOOD (2016)
Erdheim-Chester Disease as a Mimic of IgG4-Related Disease: A Case Report and a Review of a Single-Center Cohort
Davide Gianfreda et al.
MEDICINE (2016)
Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib
Kenar D. Jhaveri et al.
JAMA ONCOLOGY (2015)
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L. Diamond et al.
BLOOD (2014)
Urologic Manifestations of Erdheim-Chester Disease
Daniel A. Yelfimov et al.
UROLOGY (2014)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche et al.
BLOOD (2012)
Image of Erdheim-Chester disease requiring hemodialysis
Maki Tsukamoto et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2012)
Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α
Baptiste Hervier et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2012)
Pulmonary Involvement in Erdheim-Chester Disease A single-center study of thirty-four patients and a review of the literature
Laurent Arnaud et al.
ARTHRITIS AND RHEUMATISM (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Share Paper
